WAT · 8-K · 20260804PR331413
Acquisition / Partnership / Divestiture
WATERS CORP /DE/ · 2026-08-04 · Importance 80 · Surprise 68 · Contradicted
Waters is integrating the Biosciences and Diagnostic Solutions businesses acquired from Becton, Dickinson and Company on February 9, 2026. The acquired businesses generated $817 million of second-quarter 2026 revenue and are expected to contribute approximately $3.045 billion of reported revenue for the owned period in full-year 2026. Management said integration momentum, portfolio expansion, the larger installed base, and expected synergies are supporting its raised outlook. The company incurred $37 million of second-quarter acquisition-related costs and $119 million in the first six months, primarily for advisory, legal, accounting, tax, valuation, professional, and integration services.
Key facts
- Full-year 2026 acquired business reported revenue expectation: approximately $3,045 million on an owned-period basis. source
- Intangible assets, net at July 4, 2026: $8,521 million; at December 31, 2025: $558 million. source
- Goodwill at July 4, 2026: $9,421 million; at December 31, 2025: $1,340 million. source
- Company expects third quarter 2026 acquired business reported revenue to be approximately $895 million. source
- Acquisition of BDS included results from date of acquisition February 9, 2026 through July 4, 2026 for six months reporting. source
- Revenue from the recently acquired Biosciences and Diagnostic Solutions businesses for second quarter 2026: $817 million. source
- Acquired business contribution to total reported revenue for Q2 2026 was $817 million and accounted for the difference between total reported revenue $1,645 million and organic reported revenue $828 million. source
- Biosciences and Diagnostic Solutions revenue of $817 million exceeded guidance by $15 million and grew 4% on a prior year comparable basis. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | +157.3% | Full-year 2026 acquired business reported revenue expectation: approximately $3,045 million on an owned-period basis. |
| revenue | positive | realized | +49.7% | Acquired business contribution to total reported revenue for Q2 2026 was $817 million and accounted for the difference between total… |
| revenue | positive | committed | +46.3% | Company expects third quarter 2026 acquired business reported revenue to be approximately $895 million. |
| assets | positive | realized | +32.2% | Intangible assets, net at July 4, 2026: $8,521 million; at December 31, 2025: $558 million. |
| revenue | positive | realized | +0.9% | Biosciences and Diagnostic Solutions revenue of $817 million exceeded guidance by $15 million and grew 4% on a prior year comparable basis. |
| revenue | positive | realized | — | Acquisition of BDS included results from date of acquisition February 9, 2026 through July 4, 2026 for six months reporting. |
| revenue | positive | realized | — | Biosciences and Diagnostic Solutions revenue of $817 million exceeded guidance by $15 million and grew 4% on a prior year comparable basis. |